Full List of GSKs Scientific Presentations
|
Abstract Name |
Presenter |
Presentation Details |
|
A Phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma (MM): An interim analysis of DREAMM-9 |
Usmani S |
Poster Presentation |
|
Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): a real-world observational study update |
Hultcrantz M |
Online Publication |
|
A Phase 3, open-label, randomized study to evaluate the efficacy and safety of single agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) (DREAMM-3) |
Weisel K |
Oral Presentation |
Dostarlimab
|
Abstract Name |
Presenter |
Presentation Details |
|
Dostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Central Review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (DV66215)
|
Powell M
|
Oral Presentation |
|
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer: trial in progress (DV66345)
|
Cercek A
|
Poster Presentation |
Momelotinib
|
Abstract Name |
Presenter |
Presentation Details |
|
Impact of transfusion burden on health-related quality-of-life and functioning in myelofibrosis patients: post hoc analysis of SIMPLIFY-1 and -2 |
Mesa R |
Poster Presentation |
|
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis |
Masarova L |
Poster Presentation |
Niraparib
|
Abstract Name |
Presenter |
Presentation Details |
|
Predictors of long-term progression-free survival (PFS) in niraparib-treated patients from the PRIMA/ENGOT-OV26/GOG-3012 study (DV66092) |
Graybill W |
Poster Presentation |
|
TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors (DV66162) |
Falchook G |
Online Publication |
|
Safety and PK profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP Study (DV65716)
|
Doz F |
Poster Presentation |
Molibresib
|
Abstract Name |
Presenter |
Presentation Details |
|
Clinical Outcomes and Correlation with Longitudinal Circulating Tumor (ct)DNA Dynamics of A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer
|
Cescon D
|
Poster Presentation |
Real-world outcomes
|
Abstract Name |
Presenter |
Presentation Details |
|
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial (DV65823)
|
Mirza MR
|
Oral Presentation |
|
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab (DV64490)
|
Reck M
|
Poster Presentation |
|
Shifting perspectives on the value of non-OS endpoints and PROs: considerations across stakeholder groups to support oncology HTA decision-making (DVTBD)
|
Fameli A |
Online Publication |
|
Real-world outcomes of first-line maintenance with niraparib or bevacizumab in ovarian cancer (DV66376) |
Kudrik F |
Online Presentation |
|
PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer (DV66377) |
Kudrik F |
Online Presentation |
|
Real-world overall survival benefit in second-line maintenance niraparib monotherapy versus active surveillance in a breast cancer gene wild-type NOVA study-like subgroup of patients with recurrent ovarian cancer (DV66778) |
Coleman R |
Poster Presentation |
|
Overall survival in treated ovarian cancer patients in Argentina – OCEANIA study (DV64889) |
Abreu G |
Online Presentation |
|
Progression-free survival in patients receiving first-line platinum-based therapy in Argentina – OCEANIA study (DV64890)
|
Abreu G
|
Online Presentation |
Full list of investigator-sponsored studies and supported collaborative studies at ASCO:
Belantamab Mafodotin
|
Abstract Name |
Presenter |
Presentation Details |
|
Safety and Clinical Activity of Belantamab Mafodotin plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2, prospective, open-label, BelaRd study |
Terpos E |
Poster Presentation |
|
Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin plus Lenalidomide/Dexamethasone or Daratumumab/ Lenalidomide/Dexamethasone in two Phase 1/2 Trials |
Terpos E |
Online Publication |
Dostarlimab
|
Abstract Name |
Presenter |
Presentation Details |
|
Patients with endometrial cancer: expectations and preferences towards therapy and quality of life – first results of an international survey (NOGGO, ENGOT, GCIG - IMPROVE/EXPRESSION XI (DV66516) |
Chinczewski L |
Online Publication |
|
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting : DOMENICA STUDY (GINECO/ENGOT study) (DVTBD) |
Joly F
|
Poster Presentation |
Niraparib
|
Abstract Name |
Presenter |
Presentation Details |
|
Toxicity profile and discordance between patients/physicians regarding niraparib (NI) maintenance in recurrent ovarian cancer (ROC) patients: lessons from the NIQOLE real-life study – A Gineco study (DV66855) |
Joly F |
Poster Presentation |
|
First trial of chemotherapy de-escalation in ovarian cancer - A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy (N-PLUS/ NOGGO-ov53/ENGOT-ov62) (DV66925) |
Braicu E |
Poster Presentation |
|
Comprehensive Outcomes for After Cancer Health (COACH) Trial in Progress (DV66813) |
Lally R |
Poster Presentation |
|
A randomised phase II trial of Niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS) (DV66340) |
Fennell D |
Poster Presentation |
|
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: a phase II study (NIRA-PANC) (DV67017) |
Kasi A |
Poster Presentation |
|
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/m Head and neck squamous cell carcinoma (HNSCC) patients (DV66903) |
Zamulko O |
Poster Presentation |
|
Phase II study of niraparib and panitumumab (NIPAVECT) in advanced RAS WT colorectal cancer (DV66950) |
Olatunji B |
Poster Presentation |
|
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma |
Mehta, S |
Poster Presentation |
VEO
|
Abstract Name |
Presenter |
Presentation Details |
|
Shifting perspectives on the value of non-OS endpoints and PROs: considerations across stakeholder groups to support oncology HTA decision-making |
Fameli A |
Online Presentation |